CTLA4 and metastatic colorectal cancer: However, the clinical relevance of CTLA-4 inhibition in addition to PD-1/PD-L1 inhibition remains to be demonstrated, especially in light of the limited efficacy of durvalumab and tremelimumab in MSS metastatic colorectal cancer.23,24